Zolmitriptan reverses blink reflex changes induced during the migraine attack in humans

Neuroscience Letters

Volumn 289, Issue 1, 2000, Pages 57-60

  de Tommaso, Marina ^a   Guido, Marco ^a   Libro, Giuseppe ^a   Sciruicchio, Vittorio ^a   Puca, Francomichele ^a  

^a Roma   (Italy)

Author keywords

Blink reflex; Migraine attacks; Sumatriptan; Zolmitriptan

Indexed keywords

PLACEBO; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EYELID REFLEX; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MIGRAINE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BLINKING; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; OXAZOLES; OXAZOLIDINONES; SEROTONIN AGONISTS; SUMATRIPTAN; TRIGEMINAL GANGLION; TRYPTAMINES; VASOCONSTRICTOR AGENTS;

EID: 0034726075     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(00)01255-6     Document Type: Article

References (11)

1. Berardelli A., Cruccu G., Kimura J., Ongerboer de Visser B.W., Valls-Solè J. The orbicularis oculi reflexes. Deuschl G., Eisen A. Recommendations for the Practice of Clinical Neurophysiology: Guidelines of the International Federation of Clinical Neurophysiology, Electroencephalography and Clinical Neurophysiology. 1999;250-253 Elsevier, Amsterdam.
2. Cruccu G., Ferracuti S., Leardi M.G., Fabbri A., Manfredi M. Nociceptive quality of the orbicularis oculi reflexes as evaluated by distinct opiate and benzodiazepine-induced changes in man. Brain Res. 556:1991;209-217.
3. 1D receptor agonist 311C90. Headache. 34:1994;394-399.
4. Goadbsy P.J., Edvinsson L., Ekman R. Vasoactive peptide release in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann. Neurol. 23:1988;193-196.
5. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 8:1988;1-96.
6. Humphrey P.P.A., Feniuk W., Marriot A.S., Tanner R.J.N., Jackson M.R., Tucker M.L. Pre-clinical studies on the anti-migraine drug, sumatriptan. Eur. Neurol. 31:1991;282-290.
7. Guidelines for controlled trials of drugs in migraine. Cephalalgia. 11:1991;1-12.
8. Kaube H., Hoskin K.L., Goadsby P.J. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br. J. Pharmacol. 109:1993;788-792.
9. 1B/1D agonist for migraine. Cephalalgia. 17:1997;4-14.
10. 1B/1D: an overview of efficacy. Cephalalgia. 17:1997;28-40.
11. Schoenen J., Proietti Cecchini A., Afra J. Evidence in man for a central effect of a 5-HT1-D agonists, 311C90, from a study of the intensity dependence of the cortical evoked potentials. Eur. J. Neurol. 3:1996;88.